Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-26
2009-12-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C548S359100, C548S373100
Reexamination Certificate
active
07625937
ABSTRACT:
The present invention encompasses compounds of Formula I:or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
REFERENCES:
patent: 4349558 (1982-09-01), Bell
patent: 4349559 (1982-09-01), Bell et al.
patent: 4412995 (1983-11-01), Bell et al.
patent: 6506766 (2003-01-01), Coghlan
patent: 6831093 (2004-12-01), Scanlan et al.
patent: 7411073 (2008-08-01), Ali et al.
patent: 2003/0073703 (2003-04-01), Coghlan
patent: 2003/0176478 (2003-09-01), Scanlan et al.
patent: 0 000 471 (1978-12-01), None
patent: WO 99/41256 (1999-08-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 03/061651 (2008-07-01), None
Patani et al. [Patani, George A., Bioisosterism: a rational approach in drug design. Chem. Rev. 96 (1996) 3147-3176.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Dennler, Enrique B., New Cyclic Systems Derived from Indazole, Anales de la Asociacion Quimica Argentina, 55(3-4) (1967) 245-51.
R. Hirschmann, et al., J. Am Chem. Soc., vol. 85, p. 120, 1963.
J.H. Fried, et al., J. Am Chem. Soc., vol. 85, p. 236, 1963.
R. Hirschmann, et al., J. Am Chem. Soc., vol. 86, p. 1520, 1964.
R. Hirschmann, et al., J. Med. Chem., vol. 7, p. 352, 1964.
Abstract of Papers of the American Chem. Soc., 2001, 221, No. 260, Shah, N.; Scanlan, T.
Bioorganic & Medicinal Chemistry Letters, vol. 14, p. 5199-5203, 2004.
A. Ali, et al., Journal of Medicinal Chemistry, vol. 47, p. 2441, 2004.
R. Newton, Torax, vol. 55, p. 603,2000, “Molecular mechanisms of glucocorticoid acton: What is important?”.
Scanlan et al., STN International, HCAPLUS Database, Accession No. 2003:590999, Reg. Nos. 57102-89-6, 571202-90-9, 57120291-0, 571202-93-2, 57120294-3, 571202-95-4, 57120296-5, 571202-97-6, 571202-98-7 and 571202-99-8 (2006).
Ali Amjad
Balkovec James M.
Graham Donald W.
Quraishi Nazia
Thompson Christopher F.
Camara Valerie J.
Merck & Co. , Inc.
Saeed Kamal A
Shterengarts Samantha L
Zhao Yong
LandOfFree
1H-benzo[F]indazol-5-YL derivatives as selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-benzo[F]indazol-5-YL derivatives as selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-benzo[F]indazol-5-YL derivatives as selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086675